296 related articles for article (PubMed ID: 21742512)
21. Relationship of vaspin and apelin levels with insulin resistance and atherosclerosis in metabolic syndrome.
Karbek B; Bozkurt NC; Topaloglu O; Aslan MS; Gungunes A; Cakal E; Delibasi T
Minerva Endocrinol; 2014 Jun; 39(2):99-105. PubMed ID: 24736484
[TBL] [Abstract][Full Text] [Related]
22. Circulating visfatin in obese non-diabetic patients in relation to cardiovascular risk factors, insulin resistance, and adipocytokines: a contradictory piece of the puzzle.
de Luis DA; Sagrado MG; Aller R; Conde R; Izaola O
Nutrition; 2010; 26(11-12):1130-3. PubMed ID: 19211226
[TBL] [Abstract][Full Text] [Related]
23. Plasma apelin is lower in patients with elevated LDL-cholesterol.
Tasci I; Dogru T; Naharci I; Erdem G; Yilmaz MI; Sonmez A; Bingol N; Kilic S; Bingol S; Erikci S
Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):428-32. PubMed ID: 17647139
[TBL] [Abstract][Full Text] [Related]
24. Plasma apelin levels in subjects with nonalcoholic fatty liver disease.
Ercin CN; Dogru T; Tapan S; Kara M; Haymana C; Karadurmus N; Karslioglu Y; Acikel C
Metabolism; 2010 Jul; 59(7):977-81. PubMed ID: 20045153
[TBL] [Abstract][Full Text] [Related]
25. Serum visfatin and vaspin levels in normoglycemic first-degree relatives of Iranian patients with type 2 diabetes mellitus.
Akbarzadeh S; Nabipour I; Jafari SM; Movahed A; Motamed N; Assadi M; Hajian N
Diabetes Res Clin Pract; 2012 Jan; 95(1):132-8. PubMed ID: 22024288
[TBL] [Abstract][Full Text] [Related]
26. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease.
Yilmaz MI; Saglam M; Carrero JJ; Qureshi AR; Caglar K; Eyileten T; Sonmez A; Cakir E; Yenicesu M; Lindholm B; Stenvinkel P; Axelsson J
Nephrol Dial Transplant; 2008 Mar; 23(3):959-65. PubMed ID: 17984105
[TBL] [Abstract][Full Text] [Related]
27. Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes.
Kadoglou NP; Sailer N; Kapelouzou A; Lampropoulos S; Vitta I; Kostakis A; Liapis CD
Acta Diabetol; 2012 Aug; 49(4):269-76. PubMed ID: 21748474
[TBL] [Abstract][Full Text] [Related]
28. Cord plasma concentrations of adiponectin and leptin in healthy term neonates: positive correlation with birthweight and neonatal adiposity.
Tsai PJ; Yu CH; Hsu SP; Lee YH; Chiou CH; Hsu YW; Ho SC; Chu CH
Clin Endocrinol (Oxf); 2004 Jul; 61(1):88-93. PubMed ID: 15212649
[TBL] [Abstract][Full Text] [Related]
29. Visfatin in obese children and adolescents and its association with insulin resistance and metabolic syndrome.
Nourbakhsh M; Nourbakhsh M; Gholinejad Z; Razzaghy-Azar M
Scand J Clin Lab Invest; 2015 Apr; 75(2):183-8. PubMed ID: 25723377
[TBL] [Abstract][Full Text] [Related]
30. Circulating visfatin level is correlated with inflammation, but not with insulin resistance.
Oki K; Yamane K; Kamei N; Nojima H; Kohno N
Clin Endocrinol (Oxf); 2007 Nov; 67(5):796-800. PubMed ID: 17634078
[TBL] [Abstract][Full Text] [Related]
31. Maternal and cord blood apelin, resistin and visfatin levels in gestational diabetes mellitus.
Oncul M; Tuten A; Erman H; Gelisgen R; Benian A; Uzun H
Minerva Med; 2013 Oct; 104(5):527-35. PubMed ID: 24101110
[TBL] [Abstract][Full Text] [Related]
32. The role of leptin, soluble leptin receptor, adiponectin and visfatin in insulin sensitivity in preterm born children in prepubertal ages.
Yanni D; Darendeliler F; Bas F; Kucukemre Aydin B; Coban A; Ince Z
Cytokine; 2013 Oct; 64(1):448-53. PubMed ID: 23726672
[TBL] [Abstract][Full Text] [Related]
33. Compare the effects of different visfatin concentration on cardiovascular risk factors, adiponectin and insulin resistance in patients with T2DM.
Mohammadi S; Hosseinzadeh-Attar MJ; Hosseinnezhad A; Hosseini SH; Eshraghian MR; Nezhad MK; Rahmani M; Karimi M
Diabetes Metab Syndr; 2011; 5(2):71-5. PubMed ID: 22813406
[TBL] [Abstract][Full Text] [Related]
34. Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease.
Aktas B; Yilmaz Y; Eren F; Yonal O; Kurt R; Alahdab YO; Celikel CA; Ozdogan O; Imeryuz N; Kalayci C; Avsar E
Metabolism; 2011 Apr; 60(4):544-9. PubMed ID: 20580037
[TBL] [Abstract][Full Text] [Related]
35. Serum adiponectin and vaspin levels in rheumatoid arthritis.
Ozgen M; Koca SS; Dagli N; Balin M; Ustundag B; Isik A
Arch Med Res; 2010 Aug; 41(6):457-63. PubMed ID: 21044750
[TBL] [Abstract][Full Text] [Related]
36. Adipokines in type 1 diabetes after successful pancreas transplantation: normal visfatin and retinol-binding-protein-4, but increased total adiponectin fasting concentrations.
Stadler M; Storka A; Theuer EA; Krebs M; Vojtassakova E; Nowotny P; Pacini G; Kästenbauer T; Luger A; Prager R; Wolzt M; Anderwald C
Clin Endocrinol (Oxf); 2010 Jun; 72(6):763-9. PubMed ID: 19769621
[TBL] [Abstract][Full Text] [Related]
37. Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure.
Malyszko J; Malyszko JS; Pawlak K; Mysliwiec M
Adv Med Sci; 2008; 53(1):32-6. PubMed ID: 18635422
[TBL] [Abstract][Full Text] [Related]
38. Change of visfatin, C-reactive protein concentrations, and insulin sensitivity in patients with hyperthyroidism.
Chu CH; Lee JK; Wang MC; Lu CC; Sun CC; Chuang MJ; Lam HC
Metabolism; 2008 Oct; 57(10):1380-3. PubMed ID: 18803942
[TBL] [Abstract][Full Text] [Related]
39. Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macroangiopathy.
Alghasham AA; Barakat YA
Saudi Med J; 2008 Feb; 29(2):185-92. PubMed ID: 18246224
[TBL] [Abstract][Full Text] [Related]
40. Effect of intrauterine growth pattern on serum visfatin concentrations in full-term infants at birth and at 6 months of life.
El Shemi MS; Mohamed MH; AbdelRahman AO; Abdel Al H; Ramadan NM
J Neonatal Perinatal Med; 2016; 9(1):73-82. PubMed ID: 27002258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
